logo
Share SHARE
FONT-SIZE Plus   Neg

Theravance, Clinigen Ink Commercialization Agreement In EU For VIBATIV

Clinigen Group plc (CLIN.L) and Theravance Inc. (THRX) have reached an exclusive commercialization agreement in the European Union or EU and certain other countries in Europe for VIBATIV to treat nosocomial pneumonia, including ventilator-associated pneumonia, known or suspected to be caused by methicillin resistant Staphylococcus aureus or MRSA when other alternatives are not suitable.

VIBATIV is a bactericidal, once-daily injectable lipoglycopeptide antibacterial agent with a dual mechanism of action against Gram-positive bacteria, including resistant pathogens such as MRSA.

According to the deal, Theravance has granted Clinigen exclusive commercialization rights to VIBATIV in the EU and some other European countries, including Switzerland and Norway. Theravance, in turn, would receive a $5 million upfront payment from Clinigen and is entitled to receive tiered royalties on net sales of VIBATIV, ranging from 20% to 30%. The agreement has a term of at least 15 years, with an option to extend exercisable by Clinigen.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Aerospace and defense giant Boeing Co. on Wednesday reported a turnaround to profit in the second quarter as lower revenues were more than offset by a decline in costs and expenses. Adjusted earnings per share beat analysts' expectations, while revenues missed their estimates. Looking ahead to fiscal 2017, the company raised its outlook for earnings. Coca-Cola Company (KO) reported a profit for the second-quarter 2017 that declined 60 percent from the prior year, as the company incurred a charge of $653 million related to refranchising its North America bottling operations. The company reaffirmed full year underlying performance outlook, but raised full year comparable earnings per share target on diminished currency headwinds. Ford Motor Company (F) reported second-quarter adjusted EPS of $0.56, up $0.04 year over year. On average, 21 analysts polled by Thomson Reuters expected the company to report profit per share of $0.43 for the quarter. Analysts' estimates typically exclude special items. However, adjusted pre-tax profit...
comments powered by Disqus
Follow RTT